Descriptions like "income investor" and "value investor" are thrown around as if they're mutually exclusive. But they're not. There are many investors who equally belong to both groups.

However, it's challenging to be both an income investor and a value investor. There aren't very many stocks that provide solid dividends that are also available at an attractive valuation. That doesn't mean such stocks are impossible to find, though. Here are three dividend stocks that are dirt cheap right now.

Two people smiling as they look at a laptop screen.

Image source: Getty Images.


Shares of AbbVie (NYSE:ABBV) currently trade at just over nine times expected earnings. To put that into perspective, the forward earnings multiple for the S&P 500 stands above 21 right now. Healthcare stocks, on average, trade at more than 16 times expected earnings.

You don't just get a low valuation with AbbVie; you also get one of the best dividends around. The company is only one dividend increase away from becoming a Dividend King (S&P 500 stocks with at least 50 consecutive years of dividend increases). Its dividend yield of nearly 4.6% is enough to make most investors' mouths water.

To top it off, AbbVie should also generate pretty good growth over the next decade. That growth will be temporarily interrupted when top-selling drug Humira loses U.S. exclusivity in 2023. Except for that year, though, it seems likely that AbbVie will post solid overall sales increases.

The company has several other products that should keep the momentum going. AbbVie's blood cancer drugs Imbruvica and Venclexta continue to perform well. Its newer autoimmune disease drugs, Rinvoq and Skyrizi, could together offset much of the sales declines for Humira. The big drugmaker's acquisition of Allergan also gives it several products that should help provide growth.

Bristol Myers Squibb

Another big drugmaker, Bristol Myers Squibb (NYSE:BMY), sports an even more appealing valuation than AbbVie does. BMS stock trades at under 8.9 times expected earnings. 

The company is no slouch in the dividend department, either. Its dividend currently yields a little under 3%. And while BMS can't claim the impressive track record that equals AbbVie, it has increased its dividend payout each year over the last decade.

Top-selling drug Revlimid will face limited-volume generic competition beginning next year. However, the company's lineup includes several other blockbusters with solid sales growth, including blood thinner Eliquis and cancer immunotherapy Yervoy.

It also has several rising stars. Bristol Myers Squibb recently won a key approval for Zeposia in treating ulcerative colitis, the second approved indication for the drug. Newly approved cancer cell therapies Abecma and Breyanzi should also be big winners over the next several years.


You'll have a hard time finding a dividend stock that's cheaper than Viatris (NASDAQ:VTRS). Its shares trade at only 4.3 times expected earnings. 

Viatris initiated its dividend program in May, so it doesn't have the history of dividends that AbbVie or Bristol Myers do. The company did start out with a solid dividend, though, that yields more than 3%. It expects to increase the dividend annually.

Don't look for jaw-dropping growth from Viatris. The drugmaker was formed by the merger of Pfizer's Upjohn unit with Mylan. Upjohn was home to Pfizer's older drugs, many of which have experienced sales declines. 

Viatris' bottom line could improve, though, as it achieves cost synergies from the Upjohn-Mylan merger. Its sales should also pick up momentum within the next few years as it launches new products. For investors who prize both income and value, Viatris is definitely a stock to consider.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.